About TuHURA Biosciences
TuHURA Biosciences is a company based in Tampa (United States) founded in 1996 by Patricia Lawman and Michael Lawman.. TuHURA Biosciences has raised $41.99 million across 11 funding rounds from investors including Valirx and Kiran Patel. The company has 19 employees as of December 31, 2024. TuHURA Biosciences has completed 1 acquisition, including Kineta. TuHURA Biosciences offers products and services including IMMUNE FX (IFX), Bi-Specific Immune Modulating ADCs, IFx-2.0, IFx-3.0, and ADC: Nal – anti TIGIT. TuHURA Biosciences operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Tampa, United States
- Employees 19 as on 31 Dec, 2024
- Founders Patricia Lawman, Michael Lawman
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tuhura Biosciences, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-21.68 M-48.01as on Dec 31, 2024
-
EBITDA
$-17.53 M-18.98as on Dec 31, 2024
-
Total Equity Funding
$41.99 M (USD)
in 11 rounds
-
Latest Funding Round
$1.5 M (USD), Unspecified
Oct 27, 2025
-
Investors
Valirx
& 1 more
-
Employee Count
19
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of TuHURA Biosciences
TuHURA Biosciences is a publicly listed company on the NASDAQ with ticker symbol HURA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of TuHURA Biosciences
TuHURA Biosciences offers a comprehensive portfolio of products and services, including IMMUNE FX (IFX), Bi-Specific Immune Modulating ADCs, IFx-2.0, IFx-3.0, and ADC: Nal – anti TIGIT. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for modulating innate immune responses in diseases.
Targets for enhancing immune modulation through conjugates.
Phase 3 trial product for immune-related therapeutic applications.
Advanced immune agonist for potential disease treatment.
Specific conjugate targeting TIGIT for immune modulation.
Unlock access to complete
Leadership Team
4 people
Software Development Team
1 people
Finance and Accounting
1 people
Unlock access to complete
Funding Insights of TuHURA Biosciences
TuHURA Biosciences has successfully raised a total of $41.99M across 11 strategic funding rounds. The most recent funding activity was a Unspecified round of $1.5 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Unspecified — $1.5M
-
First Round
First Round
(12 Jan 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Unspecified - TuHURA Biosciences | Valuation |
investors |
|
| Jun, 2025 | Amount | Unspecified - TuHURA Biosciences | Valuation |
investors |
|
| Dec, 2023 | Amount | Unspecified - TuHURA Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TuHURA Biosciences
TuHURA Biosciences has secured backing from 2 investors, including institutional and angel investors. Prominent investors backing the company include Valirx and Kiran Patel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Novel oncology therapeutics and diagnostics are developed.
|
Founded Year | Domain | Location | |
|
KP
Kiran Patel |
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TuHURA Biosciences
TuHURA Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kineta. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immune-modulating therapeutics are developed for autoimmune and infectious diseases.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - TuHURA Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tuhura Biosciences Comparisons
Competitors of TuHURA Biosciences
TuHURA Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tuhura Biosciences
Frequently Asked Questions about TuHURA Biosciences
When was TuHURA Biosciences founded?
TuHURA Biosciences was founded in 1996 and raised its 1st funding round 22 years after it was founded.
Where is TuHURA Biosciences located?
TuHURA Biosciences is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Who is the current CEO of TuHURA Biosciences?
James A Bianco is the current CEO of TuHURA Biosciences.
Is TuHURA Biosciences a funded company?
TuHURA Biosciences is a funded company, having raised a total of $41.99M across 11 funding rounds to date. The company's 1st funding round was a Unspecified of $1.67M, raised on Jan 12, 2018.
How many employees does TuHURA Biosciences have?
As of Dec 31, 2024, the latest employee count at TuHURA Biosciences is 19.
What does TuHURA Biosciences do?
TuHURA Biosciences was founded in 1996 in Tampa, United States, within the biotechnology sector. Focus is placed on immunotherapies for cancer, encompassing novel personalized vaccines and inhibitors of myeloid-derived suppressor cells. Operations involve the development of candidates like the IFx-2.0 vaccine, which uses plasmid DNA injected into tumors to express immunogenic proteins. Research and clinical activities are centered in the U.S.
Who are the top competitors of TuHURA Biosciences?
TuHURA Biosciences's top competitors include Moderna, BeiGene and Strand Therapeutics.
What products or services does TuHURA Biosciences offer?
TuHURA Biosciences offers IMMUNE FX (IFX), Bi-Specific Immune Modulating ADCs, IFx-2.0, IFx-3.0, and ADC: Nal – anti TIGIT.
Is TuHURA Biosciences publicly traded?
Yes, TuHURA Biosciences is publicly traded on NASDAQ under the ticker symbol HURA.
How many acquisitions has TuHURA Biosciences made?
TuHURA Biosciences has made 1 acquisition, including Kineta.
Who are TuHURA Biosciences's investors?
TuHURA Biosciences has 2 investors. Key investors include Valirx, and Kiran Patel.
What is TuHURA Biosciences's ticker symbol?
The ticker symbol of TuHURA Biosciences is HURA on NASDAQ.